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SUMMARY 
Seventy patients suffering from primary anxiety state were selected for this clinical trial. They were 
randomly assigned to Prochlorperazine (Group I) and other drugs eg., Chlordiapoxide etc. (Group II). Hamilton's 
anxiety scale was employed to rate the anxiety. With the 4 weeks of therapy there was significant fall in score in 
both the groups of patients but the fall in score is more in Group I cases as compared to Group II (t = 11.5, df= 68, 
P < 0.001). The reduction in score (less than 10) and clinical improvement (medium to optimal improvement) was 
significantly more and faster in Group I (85%) cases as compared to Group II (70%) cases (x = 5.225, df = 1, 
P < 0.02). The side effects were least in Group I cases. 
Prochlorperazine (Stemetil) has given a significant anxiolytic effect without adversly affecting the 
mental function. In the dosage used prochlorperazine was free from the side effects and can be effectively employed 
in the management of anxiety. 
Too many drugs are being prescribed 
for the relief of anxiety and its associated 
symptoms. In 1973 more than 46 million 
prescriptions for sedatives and anti-anxiety 
drugs were dispensed by retail pharmacists 
in the National Health Services in England 
and Wales, and the increase since 1970 has 
been of the order, of one million annually 
(Tyrer 1976). Major tranquillizers eg., Ch-
lorpromazine, Promazine, Trifluoperazine, 
Fluphenazine, Oxypertine etc., in lower 
dosage are commonly given in anxiety (Ha-
milton et al 1963, Milne and Fowlier 1960). 
Their disadvantages are of producing extra-
pyramidal disorders and dependence. With 
the further studies on the phenothiazines 
(Chlorpromazine) for antiemetic effect, 
Prochlorperazine emerged out as an anti-
emetic and was less active than Chlopro-
mazine as central sedative. Clinical studies 
demonstrated its (Prochlorperazine) consi-
derably greater psychocorrective proper-
ties (St. Laurent et al 1962, Pennington 
1959, Nashipury and Moulick 1977, Ahuja 
1974). 
Drug therapy has an important place in 
the relief of anxiety but this is being eroded 
• by indiscriminate and sometimes irrespon-
sible prescriptions. Since most phenothia-
zines in low dosage have been said to be ef-
fective in the treatment of anxiety states, it 
was decided to study the value of Prochlor-
perazine (Stemetil) in the treatment of an-
xiety. 
Material and Methods 
The study was undertaken in 70 patients 
who were suffering from varying degree of 
anxiety and in whom the diagnosis of an-
xiety state was agreed upon by two consul-
tants (Nashipury and Moulick 1977, Ahuja 
1974, Ramchandran and Menon 1977). On-
ly those patients in whom anxiety was dif-
fuse and not limited to any particular object 
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or situation were taken up for the study. 
None of them were receiving any tranquil-
lizer at the time of study. A detailed case 
history was taken, physical and psychologi-
cal examination was done. Hamilton An-
xiety Scale (Hamilton 1959) was employed 
to rate the anxiety state at the beginning 
and end of the trial. 
Before the commencement of the trial 
all patients underwent basal investigations 
consisting of complete hemogram, erythro-
cyte sedimentation rate, urine and stool 
examination, liver function tests, X-ray/ 
screening of chest and electrocardiograms. 
Physiological measures eg., P.G.R., and fo-
re-arm blood flow were employed wherev-
er possible to assess anxiety. Investigations 
were carried out initially, in the middle and 
end of the trial. 
After a thorough physical and psychiatr-
ic assessment the patients were randomised 
into two groups (Ahuja 1974):-
Group 1: 40 patients who were given 
Prochlorperazine (5 mg) 2 tab-
lets three times a day or more or 
less as needed. 
Group II: 30 patients who were given 
other drugs, like Chlordiazepo-
xide, Trifluoperazine in their 
recommended doses. 
The patients were examined at pretreat-
ment level and at weekly intervals through-
out the 4 weeks trial, improvement or 
otherwise in the symptoms were noted in 
anxiety evaluation charts. As and when 
score came to less than 30 the dose of 
prochlorperazine in Group I patients were 
reduced gradually and when it came to less 
than 10 the drug was withdrawn within 
one week of time (Ahuja 1974). 
Following rating scales were used in or-
der to assess the clinical response of the pa-
tients under the trial (Dube et al 1969) :-
— 1 = worsened, 
0 = No change, 
+ 1 = Slight improvement (Score 20 to 30), 
+ 2 = Medium improvement (Score 10 to 
20) i.e., substantial recovery from 
illness, 
+ 3 = Optimal improvement (Score less 
than 10) i.e., complete recovery. 
Results 
Initially 82 patients were registered in 
this clinical trial but 70 of them could 
complete all the stages of trial. Majority of 
them were from 4th (31.4%) and 3rd 
(37.2 %) decade of life (mean age = 
33.28 ± 10.04 years) with male to female 
ratio of 4:1 (Table 1). 
Table 1 
Age and Sex distribution 
Age groups 
Upto 20 years 
21-30 years 
31-40 years 
41-50 years 
51-60 years 
Total 
Youngest 
(Years) 
Eldest (Years) 
Sex ratio 
Male 
3 
17 
20 
11 
5 
56 
18 
59 
4 : 1 
Female 
2 
9 
2 
1 
-
14 
16 
45 
Total 
5 
26 
22 
12 
5 
70 
16 
59 
Percentagi 
7.1% 
37.2% 
31.4% 
17.2% 
7.1% 
100% 
Anxiety manifested both physically and 
psychologically in these patients (Table 2). 
Somatic manifestations (Table 2 A) includ-
ed autonomic symptoms in the form of pal-
pitation (54.2 %), frequency of micturition 
(51.4%). 
Psychic manifestations were apparent 
when patients were describing it (Table 
2 B) and most of them had feeling of dread PRANESH NIGAM ET AL  229 
Table 2 
Presenting Features 
No. of 
A. Somatic and autonomic 
features : 
Palpitation 38 54.2 % 
Difficulty in breathing 32 45.7 % 
Dryness of mouth & sweating 
off and on 36 51.4% 
Nausea and vomiting with 
cold skin 25 35.7 % 
Frequency of micturition 36 51.4% 
Muscular tension, tremors and 
giddinness 42 60.0% 
Abdominal churning, gastric 
distress etc. 52 74.5% 
B. Psychic manifestations: 
Apprehension, panic and 
restlessness 68 97.1 % 
Irritability and inability to relax 38 54.3 % 
Tension with worrying over 
trivia 48 68.5 % 
Difficulty in concentration 46 65.7 % 
Insomnia 48 68.5 % 
and threat (97.1 %). Quite a good number of 
them were panicky and restless (82.8 %). 
Hamilton anxiety scale was employed 
to rate the symptoms at the begining and at 
the end of the trial, which is able to express 
quantitatively whether the improvement is 
observed clinically as compared to other 
methods (Ramchandran and Menon 1977, 
Lader and Marks 1971). In Hamilton's an-
xiety scale, the initial average score in 
Group I was 38.6 ± 6.14 and at the end of 
the trial the average score was 15.84 ± 8.16 
(Table 3). Initial average score in Group II 
patients was 36.11 ±7.15 and at the end of 
trial 18.08 ± 7.86. In both groups drugs 
caused the reduction in anxiety but on 
comparing the fall in score in these two 
groups the fall in score was significantly 
more in Group I as compared to Group II 
patients (t = 11.2, df = 68, P<0.001). 
Score during the whole period is depict-
ed in Table 4. The recovery rate was higher 
and rapid in Group I (87.5 %) as compared 
to Group II (70 %) cases which was statisti-
cally significant (X
2 = 5.22, df = 1, 
P < 0.02). The final assessment of the 
Table 4 
Score during the trial period 
Score 
Group I (n = 40) 
more than 30 
10 -30 
less than 10 
Group II (n = 30) 
more than 30 
10 - 30 
less than 10 
Before 
treatment 
25 
15 
15 
15 
-
After 
: 1 
15 
12 
15 
9 
8 
13 
treatment in 
2 
8 
8 
24 
7 
8 
15 
3 
6 
7 
27 
5 
7 
18 
4 weeks 
2(5%) 
3(7.5%) 
35 
(87.5%) 
4(13.3%) 
5(16.7%) 
21(70%) 
Comparing the two groups in attaining score less 
than 10 in 4 week time: X
2 = 5.225, df=l, P<0.02 
significant. 
Table 3 
Clinical Improvement - Analysis of Hamilton's Anxiety Scale. 
Group I (n
 : 
Initial 
Score 
= 40) 
Final 
Group II (n = 30) 
Initial Final 
Score 
Mean Score ± S. D. 
t 
df 
P 
38.6 ±6.14 15.84 ±8.16 
10.3 
39 
< 0.001 
36.1 ±7.15 18 ±7.86 
6.6 
29 
< 0.001 
Comparison of fall of score between the two groups: t = 11.2, df » 68, P<0.001 Significant 230  PROCHLORPERAZINE IN ANXIETY 
therapeutic response (Table 5) showed 
87.5% had medium to optimal improve-
ment in Group I patients while it was 70 % 
in Group II cases. 
Drug (Prochlorperazine) did not show 
any significant side effects. Slight transient 
drowsiness was noted in 3 patients (7.5 %) 
of Group I cases but it was not of an order to 
warrant reduction in dosage or withdrawal 
of the drug. Extrapyramidal side effects 
were noted in 3 cases (10 %) of Group II and 
many of them had drowsiness and dryness 
of mouth etc (5 cases or 16.6 %), which war-
ranted to reduce the dose and even withd-
rawal of drug in 2 patients of Group II. 
Discussion 
The present study was on 70 cases in 
whom anxiety manifested both bodily and 
psychologically, which are commonly des-
cribed as somatic and psychic anxiety. Both 
showed clearly as separate entities when 
analysed on anxiety rating (Hamilton et al 
1963, Hamilton 1959). Somatic group inc-
ludes autonomic symptoms that are not un-
der voluntary control and the word psychic 
has more than one meaning. Cannon 
(1979) has described the physiology of the 
symptoms. The awareness of anxiety leads 
to feeling of dread and threat and other psy-
chological symptoms. The 'fight' or 'flight' 
reaction is aroused by stimulation of the 
sympathetic nervous system, both through 
stimulation of sympathetic nerves and 
humorally by the release of adrenaline and 
other catecholamines (Tyrer 1979, 1982). 
This leads to an increase in cardiac out put 
and shunting of blood from skin and gut to 
cardiac and voluntary muscles. The somatic 
symptoms of palpitation, difficulty in 
breathing, dryness of mouth, cold skin, 
muscular tension and tremor follow rapidly 
from these physiological changes if neither 
fight not flight is appropriate. 
Many inventories and scales are avail-
able to measure the level of anxiety. In the 
present study mainly time tested and ac-
cepted Hamilton's anxiety scale was em-
ployed at the beginning and end of the trial 
to measure the levels of anxiety. Hamilton's 
anxiety scale is able to express quantitative-
ly the clinically observed improvement 
(Ramchandran and Menon 1977) and it can 
be correlated significantly with clinical 
improvement which is not possible with 
other anxiety scales (Lader and Marks 
1971). In Hamilton's anxiety scale the ini-
tial average score in Group I patients was 
36.6 ± 6.14 and at the end of the trial was 
15.86 ±8.16 and in Group II patients it 
was 36.11 ± 7.15 and 18.08 ± 7.86 respec-
tively. This showed the significant reduc-
tion in score in both the groups with the 
treatment but the reduction was signifi-
cantly more in Group I cases as compared 
to Group II cases (Table 3, t= 11.2, df = 
68, P< 0.001). 
Table 5 
Rating of Clinical response of therapy 
„ . Group I (n = 40) Group II (n = 30) 
Kltln
g No. of Cases % No. of Cases % 
- 1 or worsened 
0 or no response 
+ 1 or slight improvement 
+ 2 or medium improvement 12 30 % „7 ,- „, 
+ 3 or optimal improvement '" "
 c" 
2 
3 
12 
23 
5% 
7.5% 
30% 
57.5% 
1 
4 
4 
8 
13 
3.3 % 
13.3% 
13.3% 
26.8 % 
43.3 %  70% 
Comparing the medium and optimal improvement in two groups X
2 = 5.225, df = 1, P < 0.02 Sifnificant PRANESH NIGAM ET AL  231 
Beneficial response of prochlorperazine 
in small closes was reported in patients with 
a variety of somatic complaints leading to 
tension, uneasiness of mind and ill defined 
nervous feelings (Tyrer 1976, Milne and 
Fowler 1960, St Laurent et al 1962, Naish-
pury and Moulick 1977, Ahuja 1974). It is 
effective in geriatric patients suffering from 
anxiety and agitation associated with or-
ganic diseases. In the present series of cases 
62.5 % in Group I and 50 % in Group II had 
an initial score more than 30 and 37.5 % in 
Group I and 50 % in Group II had score bet-
ween 10-30, while no one had score less 
than 10. The recovery rate and rate of im-
provement was faster in Group I patients as 
compared to Group II cases. Ahuja (1974) 
and Nashipury and Moulick (1977) report-
ed similar results with prochlorperazine in 
low dosage in anxiety. Paterfy and Pinter 
(1972) concluded that it had comparable 
and significant anxiolytic action when ad-
ministered in low dosage. Least side effects 
had been noted with prochlorperazine 
while in Group II there was extra-pyrami-
dal effects in few patients. In view of en-
couraging results obtained prochlorperaz-
ine (Stemetil) can be effectively employed 
in the management of anxiety. 
Acknowledgement 
We express our sincere gratitude to M/s 
May and Baker (India) Ltd., Sudam Kalu 
Ahire Marg, Bombay - 400 025 for the ge-
nerous supply of drug Stemetil for the clini-
cal trial. 
References 
AHUJA, I. S. (1974), Prochlorperazine in anxie-
ty neurosis, Indian Journal of Medicine & Sur-
gery, 39 :1 
CANNON, W. B. (1979), Bodily changes in 
pain, hunger, fear and rage., Appleton, New 
York. 
DUBE, K. C, PAREKH, D. C. & YADAV, B. S. 
(1969), Phase-I, Clinical trial on GO 3315, a 
major tranquilizer, Indian Journal of Psychia-
try, 11:75. 
HAMILTON, M. (1959), The assessment of an-
xiety states by rating, British Journal of Psy-
chology, 32:50 
HAMILTON, M., HORDOEN, A., WALD-
ROP, F. N. & LOFFT, J. (1963), Controlled 
trial on the value of prochlorperazine, trif-
luoperazine and intensive group treatment, 
British Journal of Psychiatry, 109:510. 
LADER, M. & MARKS, I. (1971), Clinical An-
xiety, London William-Heinman, Page 86. 
MILNE, H. B. & FOWLER, A. B. (1960), A cli-
nical trial of chlorpromazine, prochlorperaz-
ine, methotrimeprazine, Journal of Mental 
Sciences, 106:1105. 
NASHIPURY, J. N. & MOULICK, P. (1977), 
Prochlorperazine (Stemetil) in anxiety and 
tension states, Ind. Pract., 30:61. 
PENNINGTON, V. M. (1959), Prochlorperaz-
ine in the treatment of schizophrenia. Ameri-
can Journal of Psychiatry, 115:820 
PATERFY, G. & PINTER, E.J. (1972), Compa-
rative therapeutic evaluation of anxiolytic 
drugs, Current Therapeutic Research, 24:9 
RAMCHANDRAN, V. & MENON, M. S. 
(1977), A clinical trial of Pimozide (R 6238) 
in anxiety states, Indian Journal of Psychiatry, 
19:79 
ST. LAURENT, J., COHN, C. H. & BAN, T. A. 
(1962), Treat *of Psychiatric patient with a 
pehnothiazine derivative (Prochlorperazine) 
with special reference to after care, American 
Journal of Psychiatry, 118 :938. 
TYRER, P. (1976), Drugs for anxiety Journal for 
Applied Medicine, 2 :955 
TYRER, P. (1979), Anxiety, Recent Advances in 
Clinical Psychiatry Edited by Graville-
Grossman, K. Volume 3, page 161, Churchill 
Livingstone, Edinburgh. 
TYRER, P. (1982), A major common symptom 
in Psychiatry - Anxiety, Journal for Applied 
Medicine, 9:691. WE MANUFACTURE & MARKET THE FOLLOWING" 
AQUAMIDE CAPSULES 
(Combination of Spironolactone 50 mg and Frusemtjc LP. 20 mg) 
LITHOSUN TABLETS 
(Lithium Carbonate 250 mg) 
TRAZINE-S TABLETS 
(Combination of Trifluoperazine 5 mg and 
Trihexyphenidyl 2mg) 
TRAZINE-SC TABLETS 
(Trazine-S + Chlorpronazine 50 mg) 
NITROSUN-5 TABLETS 
NITROSUN-10 TABLETS 
(Nitrazepam 5 mg & 10 mg) 
CHLORPROMAZINE TABLETS 
25 mg, 50mg& 100 mg 
PRIMOX TABLETS 
(Nortriptyline Hcl 25 mg) 
AMIXIDE TABLETS 
AMIXIDE HS TABLETS 
(Chlordiazepoxide U.S.P. 10 mg Amitriptyline Hcl U-SJ*. 25 mg) 
and 
(Chlordiazepoxide U.SJ*. 5 mg+Amitriptyline HCl U.S.P. 25 mg) 
SUN PHARMACEUTICAL INDUSTRIES 
Cl/2710, G.I.D.C, III PHASE 
VAPI - 396195 • GUJARAT 